BrainStorm Cell Therapeutics Submits IND Amendment to FDA, Paving the Way for Phase 3b Trial of NurOwn® in ALS

miRNA-Based Therapy Shows Promise in Phase II for ALS

The field of microRNA (miRNA) took a step forward when NeuroSense announced promising new findings from its Phase II trial of its PrimeC in amyotrophic lateral sclerosis (ALS). The trial not only reinforced the drug’s potential but shed more light on how miRNA-based therapeutics work. The data “reveal the consistent effect of PrimeC on altering the expression of miRNAs associated with ALS, reinforcing its potential role in addressing key patholo…

ALS Association, Schoox partner to provide education resources

The ALS Association is teaming with the workplace learning company Schoox to provide education resources for patients, caregivers, healthcare providers, and others affected by amyotrophic lateral sclerosis (ALS). With this partnership, Schoox will provide fast and easy access to a range of resources, including educational materials and programs for ALS patients and caregivers, and certification courses for providers. “The ALS community looks to …

College of Medicine joins research team testing the impact of video on visit communication for people with ALS

The Department of Neurology at Penn State College of Medicine and Penn State Neuroscience Institute are part of a research group that has received a five-year, $13 million funding award from the Patient-Centered Outcomes Research Institute (PCORI). Their project will test the effectiveness of video as a communication tool during patient visits for people living with Amyotrophic Lateral Sclerosis… Source

BrainStorm Cell Therapeutics Submits IND Amendment to FDA, Paving the Way for Phase 3b Trial of NurOwn® in ALS

NEW YORK, April 10, 2025 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading biotechnology company developing cutting-edge cell therapies for neurodegenerative diseases, today announced the submission of an Investigational New Drug (IND) amendment to the U.S. Food and…